Physician profile
Amin Farah
NPI 1902908080
$5,894.87
in general payments reported to CMS, 2019-2025
26 companies · $896 in 2025
The $896 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $732 · 2021: $1,033 · 2022: $744 · 2023: $974 · 2024: $1,110 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,217.54 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $852.44 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $774.21 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $427.88 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $380.13 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $380.05 | 2020-2025 | Brilinta, Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $274.82 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $258.15 | 2019-2025 | |
| Scpharmaceuticals INC. | $207.75 | 2023-2025 | |
| Edwards Lifesciences Corporation | $140.99 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $121.16 | 2022-2023 | Praluent, Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $113.68 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $111.16 | 2019 | |
| Abiomed | $97.34 | 2023-2024 | Impella |
| Boston Scientific Corporation | $86.50 | 2021-2023 | Watchman Flx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.77 | 2021-2023 | Repatha |
| Medtronic, INC. | $65.95 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $58.28 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $55.50 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.12 | 2022 | |
| Kestra Medical Technology Services, INC. | $42.91 | 2022-2025 | Assure Wcd |
| Ionis Pharmaceuticals, INC. | $29.98 | 2025 | Tryngolza |
| Esperion Therapeutics, INC. | $24.81 | 2023 | Nexletol |
| Cvrx, INC. | $24.62 | 2022 | |
| Preventice Services, LLC | $20.73 | 2021 | |
| Medtronic Vascular, INC. | $17.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amin Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.